Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.

about

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.

Item

http://www.wikidata.org/entity/Q38663481

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.

@en

type

Item

label

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.

@en

prefLabel

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.

@en

P1476

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia

@en

P2093

John H Schoonover

http://www.w3.org/2001/XMLSchema#string

Kate G Moore

http://www.w3.org/2001/XMLSchema#string

Michael Shtutman

http://www.w3.org/2001/XMLSchema#string

Samuel G Johnson

http://www.w3.org/2001/XMLSchema#string

Whitney D Maxwell

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association of lipid-lowering response to statins in combined study populations

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

Pharmacogenomics knowledge for personalized medicine

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin

Impact of apolipoprotein A5 variants on statin treatment efficacy

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

P304

1172-1190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1981

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laura B Ramsey

Marina Kawaguchi-Suzuki

P577

2017-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28672099

http://www.w3.org/2001/XMLSchema#string

P921

statin therapy

dyslipidemias